Therapeutic strategies targeting TGF-β signaling in cancer encompass approaches based on RNA interference of TGF-β1 and TGF-β2 [60], inhibition of TGF-β signaling via small-molecule inhibitors of TGF-β receptor kinases (TGFBRIs) [61], neutralizing antibodies against TGF-β ligands, and so-called TGF-β trap receptors, which are essentially “decoys” for TGF-β ligands, representing a modified version of the TGF-β receptor or its fragment that exhibits high affinity for TGF-β ligands such as TGF-β1, TGF-β2, and TGF-β3 [62], as well as antisense oligonucleotides [63]. The gene discussed is TGFB2; the disease is cancer.